Medigus Ltd. Logo

Medigus Ltd.

MDGS

(1.5)
Stock Price

2,36 USD

-15.28% ROA

-61.48% ROE

-0.51x PER

Market Cap.

5.462.264,00 USD

25.89% DER

0% Yield

-13.06% NPM

Medigus Ltd. Stock Analysis

Medigus Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Medigus Ltd. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.12x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a low debt to equity ratio (26%), which means it has a small amount of debt compared to the ownership it holds

3 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

4 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (7), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

5 ROE

The stock's ROE indicates a negative return (-23.11%) on shareholders' equity, suggesting poor financial performance.

6 ROA

The stock's ROA (-15.28%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

9 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

10 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

11 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

Medigus Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Medigus Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Medigus Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Medigus Ltd. Revenue
Year Revenue Growth
2012 802.743
2013 717.301 -11.91%
2014 684.142 -4.85%
2015 618.906 -10.54%
2016 549.000 -12.73%
2017 467.000 -17.56%
2018 436.000 -7.11%
2019 273.000 -59.71%
2020 531.000 48.59%
2021 -1.476.000 135.98%
2022 91.858.000 101.61%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Medigus Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2012 2.074.980
2013 2.348.887 11.66%
2014 3.698.320 36.49%
2015 4.360.011 15.18%
2016 3.655.000 -19.29%
2017 2.208.000 -65.53%
2018 1.809.000 -22.06%
2019 609.000 -197.04%
2020 997.000 38.92%
2021 1.092.000 8.7%
2022 4.853.000 77.5%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Medigus Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 1.256.444
2013 1.974.731 36.37%
2014 2.107.383 6.29%
2015 2.825.041 25.4%
2016 3.684.000 23.32%
2017 3.005.000 -22.6%
2018 3.338.000 9.98%
2019 13.179.000 74.67%
2020 5.494.000 -139.88%
2021 28.036.000 80.4%
2022 14.174.000 -97.8%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Medigus Ltd. EBITDA
Year EBITDA Growth
2012 -3.293.147
2013 -8.229.720 59.98%
2014 -8.680.177 5.19%
2015 -9.485.201 8.49%
2016 -9.017.000 -5.19%
2017 -5.960.000 -51.29%
2018 -6.778.000 12.07%
2019 -14.455.000 53.11%
2020 -7.887.000 -83.28%
2021 42.736.000 118.46%
2022 -11.988.000 456.49%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Medigus Ltd. Gross Profit
Year Gross Profit Growth
2012 491.978
2013 393.970 -24.88%
2014 362.616 -8.65%
2015 344.036 -5.4%
2016 373.000 7.77%
2017 -49.000 861.22%
2018 -171.000 71.35%
2019 -182.000 6.04%
2020 -503.000 63.82%
2021 -3.572.000 85.92%
2022 14.452.000 124.72%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Medigus Ltd. Net Profit
Year Net Profit Growth
2012 -3.280.031
2013 -1.490.022 -120.13%
2014 -5.811.353 74.36%
2015 -9.479.565 38.7%
2016 -9.007.000 -5.25%
2017 -2.545.000 -253.91%
2018 -6.598.000 61.43%
2019 -14.178.000 53.46%
2020 -6.850.000 -106.98%
2021 23.460.000 129.2%
2022 -10.208.000 329.82%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Medigus Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 -785 100%
2017 -61 -1208.33%
2018 -47 -27.66%
2019 -54 12.96%
2020 -15 -260%
2021 26 160%
2022 -6 516.67%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Medigus Ltd. Free Cashflow
Year Free Cashflow Growth
2012 -1.714.385
2013 -6.588.130 73.98%
2014 -7.824.999 15.81%
2015 -7.064.999 -10.76%
2016 -9.297.000 24.01%
2017 -4.690.000 -98.23%
2018 -4.233.000 -10.8%
2019 -2.757.000 -53.54%
2020 -6.467.000 57.37%
2021 -2.349.000 -175.31%
2022 -5.730.000 59.01%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Medigus Ltd. Operating Cashflow
Year Operating Cashflow Growth
2012 -1.611.538
2013 -6.502.191 75.22%
2014 -7.757.000 16.18%
2015 -6.981.000 -11.12%
2016 -9.265.000 24.65%
2017 -4.681.000 -97.93%
2018 -4.222.000 -10.87%
2019 -2.695.000 -56.66%
2020 -6.143.000 56.13%
2021 -2.340.000 -162.52%
2022 -5.656.000 58.63%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Medigus Ltd. Capital Expenditure
Year Capital Expenditure Growth
2012 102.847
2013 85.938 -19.68%
2014 68.000 -26.38%
2015 84.000 19.05%
2016 32.000 -162.5%
2017 9.000 -255.56%
2018 11.000 18.18%
2019 62.000 82.26%
2020 324.000 80.86%
2021 9.000 -3500%
2022 74.000 87.84%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Medigus Ltd. Equity
Year Equity Growth
2013 11.127.064
2014 13.034.646 14.63%
2015 10.177.116 -28.08%
2016 2.927.000 -247.7%
2017 5.511.000 46.89%
2018 8.079.000 31.79%
2019 8.131.000 0.64%
2020 26.194.000 68.96%
2021 51.433.000 49.07%
2022 54.689.000 5.95%
2023 44.447.000 -23.04%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Medigus Ltd. Assets
Year Assets Growth
2013 12.979.182
2014 14.273.241 9.07%
2015 12.135.791 -17.61%
2016 4.724.000 -156.9%
2017 7.210.000 34.48%
2018 11.239.000 35.85%
2019 13.334.000 15.71%
2020 32.335.000 58.76%
2021 59.730.000 45.86%
2022 97.651.000 38.83%
2023 85.667.000 -13.99%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Medigus Ltd. Liabilities
Year Liabilities Growth
2013 1.852.118
2014 1.238.594 -49.53%
2015 1.958.675 36.76%
2016 1.797.000 -9%
2017 1.699.000 -5.77%
2018 3.160.000 46.23%
2019 5.203.000 39.27%
2020 6.141.000 15.27%
2021 8.297.000 25.99%
2022 42.962.000 80.69%
2023 41.220.000 -4.23%

Medigus Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
56.5
Net Income per Share
-6.28
Price to Earning Ratio
-0.51x
Price To Sales Ratio
0.06x
POCF Ratio
-0.92
PFCF Ratio
-0.95
Price to Book Ratio
0.13
EV to Sales
-0.05
EV Over EBITDA
0.37
EV to Operating CashFlow
0.79
EV to FreeCashFlow
0.78
Earnings Yield
-1.96
FreeCashFlow Yield
-1.05
Market Cap
0,01 Bil.
Enterprise Value
0,00 Bil.
Graham Number
58.32
Graham NetNet
1.17

Income Statement Metrics

Net Income per Share
-6.28
Income Quality
0.56
ROE
-0.23
Return On Assets
-0.25
Return On Capital Employed
-0.29
Net Income per EBT
1.08
EBT Per Ebit
1.4
Ebit per Revenue
-0.09
Effective Tax Rate
-0.02

Margins

Sales, General, & Administrative to Revenue
0.15
Research & Developement to Revenue
0.05
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.15
Operating Profit Margin
-0.09
Pretax Profit Margin
-0.12
Net Profit Margin
-0.13

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0.41
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-3.48
Free CashFlow per Share
-3.52
Capex to Operating CashFlow
0.01
Capex to Revenue
-0
Capex to Depreciation
-0.02
Return on Invested Capital
-0.28
Return on Tangible Assets
-0.15
Days Sales Outstanding
100.26
Days Payables Outstanding
96.29
Days of Inventory on Hand
8.45
Receivables Turnover
3.64
Payables Turnover
3.79
Inventory Turnover
43.22
Capex per Share
-0.05

Balance Sheet

Cash per Share
15,41
Book Value per Share
24,08
Tangible Book Value per Share
14.66
Shareholders Equity per Share
24.08
Interest Debt per Share
3.72
Debt to Equity
0.26
Debt to Assets
0.1
Net Debt to EBITDA
0.83
Current Ratio
1.39
Tangible Asset Value
0,02 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
0.26
Working Capital
0,01 Bil.
Intangibles to Total Assets
0.32
Average Receivables
0,01 Bil.
Average Payables
0,01 Bil.
Average Inventory
1509000
Debt to Market Cap
1.86

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Medigus Ltd. Dividends
Year Dividends Growth
2022 1

Medigus Ltd. Profile

About Medigus Ltd.

Medigus Ltd., a technology-based company, provides medical-related devices and products in the United States, Europe, China, Israel, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it develops, markets, and distributes software for internet users; and operates online stores for the sale of various consumer products on the Amazon online marketplace, as well as an online event management and ticketing platform. Further, the company develops, produces, and markets miniaturized imaging equipment, visualization solutions, and resistant cameras; electric vehicles; and wireless vehicle battery charging technologies. Medigus Ltd. was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel.

CEO
Mr. Liron Carmel
Employee
77
Address
Building B
Tel Aviv, 6971068

Medigus Ltd. Executives & BODs

Medigus Ltd. Executives & BODs
# Name Age
1 Mr. Liron Carmel
Chief Executive Officer
70
2 Ms. Tali Dinar
Chief Financial Officer
70
3 Dr. Yaron Silberman
Chief Executive Officer of ScoutCam Ltd.
70
4 Ilan Oren
Executive Officer
70

Medigus Ltd. Competitors